Company Filing History:
2 out of 2 
1 out of 83 Years Active: 2002-2018
Title: Ho Sun Son: Innovator in Vaccinia Virus Research
Introduction
Ho Sun Son is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of virology, particularly in the development of vaccines using the vaccinia virus. With a total of 3 patents, his work has the potential to impact public health positively.
Latest Patents
One of his latest patents is the "Attenuated vaccinia virus KVAC103 strain." This strain was developed by subculturing a vaccinia virus strain 103 times in VERO cells. The KVAC103 strain exhibits significantly low toxicity and reduced skin lesions while effectively inducing immune responses to poxvirus. This makes it a promising candidate for use as a poxvirus vaccine with fewer side effects.
Another notable patent is the "Recombinant vaccinia virus derived from KVAC103 strain." This invention involves a novel recombinant virus vector obtained by inserting an exogenous gene into the KVAC103 strain. The recombinant virus vector serves as a safe vaccine delivery vehicle in mammals. It has an enhanced ability to proliferate in cultured cells, making it easier to produce. Additionally, these recombinant viruses express a higher level of an exogenous antigen, leading to improved immunogenic efficacy. Such vectors can be utilized in vaccines for disease prevention, therapeutic vaccines, and molecular biological studies.
Career Highlights
Ho Sun Son has worked with reputable organizations, including the Korea Centers for Disease Control and Prevention and LG Chem. His experience in these institutions has contributed to his expertise in vaccine development and virology.
Collaborations
Throughout his career, Ho Sun Son has collaborated with notable colleagues, including Sang Gu Yeo and Sang Won Lee. These partnerships have likely enhanced his research and innovation efforts.
Conclusion
Ho Sun Son's contributions to the field of virology, particularly through his patents on the attenuated vaccinia virus and recombinant virus vectors, demonstrate his commitment to advancing vaccine technology. His work holds promise for improving public health outcomes through safer and more effective vaccines.